Preliminary Program - American Association of Pharmaceutical ...

More documents

Recommendations

Info

SM 64 2009 AAPS Annual Meeting and Exposition AAPS Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Programming at a glance Sunday Monday Tuesday Wednesday Thursday 8:30 am – 4:00 pm Short Course #1 RNA-targeting Therapeutics: Issues and Advances An additional fee is required to attend this short course Short Course #5 Transportermediated Drug-drug Interactions: Possible Criteria that Warrant In Vivo Transportermediated DDI Studies via In Vitro Assessments An additional fee is required to attend this short course 8:00 am – 10:00 am Monday Morning Roundtables Funded by a Grant from Roundtables Biotherapeutics and Modulation of Drug Transporters Optimization of Systemic Exposure in Preclinical and Clinical Development: “Success Stories” of Proven Methods for Challenging Drug Candidates – What You Did Not Already Know! 2:00 pm – 4:30 pm Monday Afternoon Symposia Funded by a Grant from SymposiA AAPS/ACCP Joint Symposium: Strategic Biomarkers for Treating Diseases in Younger Children Safely and Effectively The Modeling and Simulation Frontier: Multi-level, Multiscale, Multi-attribute, Adaptable, and Extensible Discrete Event Models 7:00 am – 8:15 am Sunrise Sessions The Blood Brain Barrier The Story of the Three Bears: Too Big, Too Small, Just Right! Size Issues in Drug Development 8:30 am – 11:00 am AAPS Graduate Student Symposium in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and Clinical Pharmacology and Translational Research (PPDM & CPTR) Sponsored by During this Symposium, a presentation from the Research Achievement Award winner will be given. AAPS Research Achievement Award in Clinical Pharmacology and Translational Research Sponsored by 9:00 am – 11:00 am Roundtable To Test or Not to Test? Risk Assessment Approaches for Human Metabolites 2:00 pm – 4:00 pm Tuesday Afternoon Roundtables Funded by a Grant From Roundtable Inclusion of Women in Clinical Trials and Drug Development – How Far Have We Gone 2:00 pm – 4:30 pm Symposia Reactive Metabolites in Drug Discovery and Development: How Can We Handle the Risk? Pros and Cons of Emerging Methods in Population PK and Exposure/ Response Analysis Leveraging Prior Quantitative Knowledge in Guiding Pediatric Drug Development 7:00 am – 8:15 am Sunrise Sessions Minimizing the Guesswork of Early Human Dose Predictions: Application of PK Prediction Methodologies Including PBPK Today, Tomorrow, and Beyond: Approaches and Challenges in Modeling Pharmacodynamic Effects with Long Time Delays Pharmacogenetics: Methods and Clinical Applications 8:30 am – 11:00 am Wednesday Morning Symposia Funded by a Grant from Symposia Pharmacoproteomics: Targeted Absolute Quantitative Proteomics in ADME Pharmacokinetic-pharmacodynamic Aspects of Inhaled Lung-targeted Agents 9:00 am – 11:00 am Roundtables Facilitating the Transition to Modelbased Drug Development Impact of Pharmacogenomics on Drug Development: An Industrial Perspective Translational Challenges in PK/PD/TD of Biotechnology-derived Products 2:00 pm – 4:00 pm Roundtable In Vivo Animal Models for Prediction of Drug-drug Interactions 2:00 pm – 4:30 pm wednesday afternoon symposia funded by a grant from Symposia Mechanism-based PKPD Modeling: Its Role in Discovery and Early Development of Biologics Microdialysis Role in the Development and Optimization of Drug Topical Delivery The Graying Globe — Drug Development in the Elderly 7:00 am – 8:15 am Sunrise Sessions Humanized Transgenic Transporter Models — Update on State-of-the-Art Physiologically Based Pharmacokinetic Modeling: Concepts and Applications in Drug Discovery and Development Modeling Ophthalmic Drug Delivery and Disposition 8:30 am – 11:00 am Symposia The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration Using Modeling and Simulation to Safely Adjust Dose Regimens for Obese Patients 9:00 am – 11:00 am Roundtables First Time in Human Dosing – Gimmicks, Luck, and Science Predicting Oral Drug Absorption: Fiction and Facts Evaluating Fit-for-Purpose Models: Consensus or Controversy 1:30 pm – 5:00 pm Open Forum An Evolution or Revolution in Drug Metabolism: When, Where, Why, What, How? An additional fee is required to attend this open forum.
65 2009 AAPS Annual Meeting and Exposition AAPS Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Programming New INTERACTIVE FEATURE for all Roundtable Sessions! Click on roundtable moderator names to submit questions that you would like to be addressed at the roundtable session in Los Angeles. Sunday, November 8, 2009 Sunday, November 8, 2009 8:30 am - 4:00 pm RNA-targeting Therapeutics: Issues and Advances Short Course #1 An additional fee is required to attend this short course. The use of oligonucleotides as therapeutic agents has elicited a great deal of interest. Basic understanding of the pharmacokinetics and delivery of antisense oligonucleotides and siRNA as tools for silencing genes or regulatory RNAs is foundational to their appropriate design and application. The short course will consist of the following lecture topics: basic knowledge of siRNA and antisense and in vivo uptake mechanisms/ pathways of oligonucleotide uptake into cells, overview of RNA-targeting therapeutics-basic primer, siRNA promise and challenges of RISC based targeting of mRNA, specific in vivo targeting of siRNA advances and challenges, antisense advances and challenges of single-strand, pharmacokinetics and ADME characterization of siRNA in animal models, pharmacokinetics and ADME characterizations of siRNA in humans, MicroRNA, a new target for RNAtargeting therapeutics, and regulatory pathways for oligonucleotide therapeutics. Moderators Pei Fan (Jane) Bai, Ph.D. U.S. Food and Drug Administration Richard Geary, Ph.D. ISIS Pharmaceuticals, Inc. Antisenseantisense: Advances and Challenges of Single-strand Antisense Richard Geary, Ph.D. ISIS Pharmaceuticals, Inc. Uptake Mechanisms of Oligoneucleotides Frank Bennett, Ph.D. ISIS Pharmaceuticals, Inc. Therapeutic Development of MicroRNA: Promises and Challenges Peter Linsley, Ph.D. Merck and Co., Inc. Progress in the Delivery of siRNA Mark Tracy, Ph.D. Alnylam Pharmaceuticals Oligonucleotide Therapeutics: Regulatory Pathway Pei Fan (Jane) Bai, Ph.D., invited U.S. Food and Drug Administration Clinical Pharmacokinetic and Safety Studies of RNAi in Humans John DeVincenzo, Ph.D. University of Tennessee Health Science Center 8:30 am – 4:00 pm Transporter-mediated Drug-drug Interactions: Possible Criteria that Warrant In Vivo Transporter-mediated DDI Studies via In Vitro Assessments Short Course #5 An additional fee is required to attend this short course It is widely recognized that membrane transporters play an important role in modulating drug absorption, distribution, and elimination. Superfluity of publications in the recent years advances the understanding of these processes, and enables the interpretation of underlying mechanisms responsible for the modification of pharmacokinetic and pharmacodynamics. Furthermore, an increased interest has been shown by both regulatory agencies and pharmaceutical industry to understand the potential clinical implications of transporter-mediated drug-drug interactions for new drugs. For pharmaceutical scientists, the challenge ahead will be the successful translation of this basic awareness of drug transporters to applications in drug discovery and development. This short course will introduce the basic concepts of drug transport, the role of transporters in drug-drug interactions (DDI), the role of transporters in toxicity, models for characterizing drug transporters, and give examples of translation of preclinical knowledge into the clinical setting. Moderators Yurong Lai, Ph.D. Pfizer, Inc. Joseph Polli, Ph.D. GlaxoSmithKline plc Overview of Efflux Transporters Mediated Drug-drug Interaction Douglas H. Sweet, Ph.D. Virginia Commonwealth University Overview of Uptake Transporters Mediated Drug-drug Interaction Richard Kim, Ph.D. University of Western Ontario In Vitro Drug Transport Drug Interaction Studies-Design, Data Analysis, and Recommendation for Clinical Studies Shiew Mei Huang, Ph.D., invited U.S. Food and Drug Administration Possible Criteria that Warrant In Vivo Renal Transporters Mediated DDI Studies and In Vitro Assessments Kathy Giacomini, Ph.D. University of California, San Fransisco Possible Criteria that Warrant In Vivo Hepatic Transporters Mediated DDI Studies and In Vitro Assessments Yurong Lai, Ph.D. Pfizer, Inc. Possible Criteria that Warrant In Vivo Gastrointestinal Efflux Transporters-mediated DDI Studies and In Vitro Assessments Joseph Polli, Ph.D. GlaxoSmithKline plc Monday, November 9, 2009 MONDAY MORNING ROUNDTABLES Funded by a Grant from 8:00 am – 10:00 am Biotherapeutics and Modulation of Drug Transporters Roundtable Therapeutic proteins (cytokines, interleukins, and monoclonal antibodies) are becoming widely popular for many therapeutic area and diseases. However, the interaction of drug transporters/ enzymes and biotherapeutics remains largely unknown. It has been shown that interferons can have an impact on drug transporters that may alter the pharmacokinetics and pharmacodynamics of a conventional drug. For example, interferon-alpha induces a significant dose-dependent inhibitory effect on P-gp intestinal activity and results in increased bioavailability of digoxin. The findings could have important clinical relevance because interferon-alpha is widely used in cancer, antiviral therapy, and could be associated with efflux transporter substrates, such as anticancer drugs. The goal of this session is to increase awareness among the audience about this rapidly emerging area, and to share case studies that highlight the interplay between these systems.
Page 1 and 2:
Preliminary Program 2009 AAPS Annua
Page 3 and 4:
Letter from the Mayor
Page 5 and 6:
5 2009 AAPS Annual Meeting and Expo
Page 7 and 8:
aaPS SuStaining SPonSor AAPS HonorS
Page 9 and 10:
2009 ANNUAL MEETING and EXPOSITION
Page 11 and 12:
11 2009 AAPS Annual Meeting and Exp
Page 13 and 14: 13 2009 AAPS Annual Meeting and Exp
Page 17 and 18: SM 17 2009 AAPS Annual Meeting and
Page 21 and 22: aaPS SuStaining SPonSor AAPS HonorS
Page 63: 63 2009 AAPS Annual Meeting and Exp
Page 67 and 68: SM 67 2009 AAPS Annual Meeting and
Page 101 and 102: 101 2009 AAPS Annual Meeting and Ex
Page 103 and 104: 103 2009 AAPS Annual Meeting and Ex
Page 105: 105 2009 AAPS Annual Meeting and Ex
show all

Preliminary Program - American Association of Pharmaceutical ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?